Purpose: The number of obese patients seeking total hip arthroplasty (THA) continues to expand despite body mass index (BMI) cutoffs. We sought to determine the outcomes of THA in the morbidly obese patient, and hypothesized they would have comparable outcomes to two cohorts of obese, and normal weight patients. Materials and Methods: THA performed on morbidly obese patients (BMI >40 kg/m2 ) at a single academic center from 2010 until 2020 were retrospectively reviewed. Eighty morbidly obese patients were identified, and matched in a 1:3:3 ratio to control cohorts with BMI 30-40 kg/m2 and BMI <30 kg/m2 . Acute postoperative outcomes and BMI change after surgery were evaluated for clinical significance with univariate and regression analyses. Cox proportional hazard ratio was calculated to evaluate prosthetic joint infection (PJI) and revision surgery through follow-up. Mean follow-up was 3.9 years. Results: In the acute postoperative period, morbidly obese patients trended towards increased hospital length of stay, facility discharge and 90-day hospital returns. At final follow-up, a higher percentage of morbidly obese patients had clinically significant (>5%) BMI loss; however, this was not significant. Cox hazard ratio with BMI <30 kg/m 2 as a reference demonstrated no significant difference in survival to PJI and all-cause revision in the morbidly obese cohort. Conclusion Morbidly obese patients (BMI >40 kg/m2 ) require increased resource expenditure in the acute postoperative period. However, they are not inferior to the control cohorts (BMI <30 kg/m2 , BMI 30-40 kg/m2 ) in terms of PJI or all-cause revisions at mid-term follow-up.

OBJECTIVE: To test the hypothesis that β -glucan enhances protective qi (PQi), an important Chinese medicine (CM) concept which stipulates that a protective force circulates throughout the body surface and works as the first line of defense against "external pernicious influences". METHODS: A total of 138 participants with PQi deficiency (PQD) were randomized to receive β -glucan (200 mg daily) or placebo for 12 weeks. Participants' PQi status was assessed every 2 weeks via conventional diagnosis and a standardized protocol from which a PQD severity and risk score was derived. Indices of participants' immune and general health status were also monitored, including upper respiratory tract infection (URTI), saliva secretory IgA (sIgA), and self-reported measures of physical and mental health (PROMIS). RESULTS: PQi status was not significantly different between the β -glucan and placebo treatment groups at baseline but improved significantly in the β -glucan (vs. placebo) group in a time-dependent manner. The intergroup differences [95% confidence interval (CI)] in severity score (scale: 1-5), risk score (scale: 0-1), and proportion of PQD participants (%) at finish line was 0.49 (0.35-0.62), 0.48 (0.35-0.61), and 0.36 (0.25-0.47), respectively. Additionally, β -glucan improved URTI symptom (scale: 1-9) and PROMIS physical (scale: 16.2-67.7) and mental (scale: 21.2-67.6) scores by a magnitude (95% CI) of 1.0 (0.21-1.86), 5.7 (2.33-9.07), and 3.0 (20.37-6.37), respectively, over placebo. CONCLUSIONS β -glucan ameliorates PQi in PQD individuals. By using stringent evidence-based methodologies, our study demonstrated that Western medicine-derived remedies, such as β -glucan, can be employed to advance CM therapeutics. (ClinicalTrial.Gov registry: NCT03782974).
Adult ; Double-Blind Method ; Humans ; Qi ; Risk Factors ; Self Report ; beta-Glucans/therapeutic use*

The prevalence of non-communicable diseases (NCDs) across the globe has reached epidemic proportions, with more than three quarters of NCD deaths now occurring in low- and middle-income countries (LMIC).1 NCDs encompass a broad range of chronic conditions, which include cardiovascular diseases, cancers, chronic respiratory diseases, diabetes, and mental disorders.2 To mitigate the growing global NCD burden and its associated challenges, upscaling high-impact essential interventions for the prevention and control of NCDs has remained a priority, especially in low-resource settings. One such intervention is strengthening self-care strategies or self-management of individuals living with NCDs.3 In the past few decades, the self-management approach to NCD has proven to be a cost-effective strategy to improve a patient’s quality of life by reducing symptom severity and decreasing pain. This approach has also encouraged patients to become key decision makers in the treatment process.4 Self-management includes both technological (e.g. smartphone applications, telemonitoring systems, or wearable devices) and non-technological interventions (social support, educational materials, or in-person training seminars).5 Telemedicine has played several important roles in the whole spectrum of care for patients with NCD. These include promotion of healthy behaviors, prevention of risk factors, prompt recognition and initiation of treatment, disease monitoring and follow-up, rehabilitation, and palliation. Telemedicine not only increases access to health care but also improves the quality of health care especially in rural areas.6 7 The unique challenges resulting from the COVID-19 pandemic has limited patient access to health care, especially in geographically isolated and disadvantaged areas. This literature review aims to determine the effectiveness of telemedicine on clinical and psychosocial outcomes of adult patients diagnosed with NCDs. We conducted a literature search on PubMed, EBSCOhost, ProQuest, Google Scholar, and Gale using the search words “telemedicine,” “adult,” “non-communicable disease,” “self-management,” and “teleconsultation.” We filtered the results to only include randomized controlled trials (RCT). To narrow down the scope of this literature review, only previous studies that compared telemedicine and usual care (non-telemedicine) among adults with non-communicable diseases, and those that report clinical and psychosocial outcomes—i.e., symptom outcomes, laboratory outcomes, knowledge on disease, or behavior outcomes that pertain to self-management of disease—were assessed. We excluded studies if they were done among patients <18 years old, if they included telemedicine that supplemented rather than replaced the usual (face-to-face) care, if they were not able to report outcomes between groups, or if they did not meet the criteria of a RCT. Two reviewers independently reviewed the abstracts yielded from the search strategy and assessed them based on the set criteria. If neither reviewer was able to rule out an article based on the abstract, the full text was retrieved and assessed to determine inclusion into the study. After the final assessment, a total of 9 RCT reports were included in this review. The general characteristics and key findings of the 9 studies included in this literature review are summarized in Table 1. The included studies, published in various journals between 2014 and 2021, were carried out in eight countries—two studies were done in Australia, and one each in Bangladesh, India, Italy, USA, Germany, China, and the Netherlands. The studies enrolled patients who were diagnosed with type 2 diabetes mellitus (DM) (n=3), chronic obstructive pulmonary disease (n=1), type 1 DM (n=1), congestive heart failure (n=1), stroke (n=1), osteoarthritis (n=1), and various non-specific chronic conditions, including type 2 DM, hypertension, coronary artery diseases, heart failure, chronic depression, and schizophrenia (n=1). The sample sizes of the studies included ranged from 29 to 10,815 participants. Follow-up periods ranged from 3 to 36 months. The telemedicine techniques that were used in the studies included mobile phone-based health interventions, telemedicine-based visits, and telephone-based health coaching. In general, most of the studies included in this review reported that telemedicine is as good as, if not better than, usual care approaches in achieving clinical and psychosocial outcomes.
Noncommunicable Diseases ; Chronic Disease

Purpose: Outpatient classified total hip arthroplasty (THA) is a safe option for a select group of patients. An analysis of a national database was conducted to understand the risk factors for unplanned discharge to a skilled nursing facility (SNF) or acute rehabilitation (rehab) after outpatient classified THA. Materials and Methods: A query of the National Surgical Quality Improvement Program (NSQIP) database for THA (Current Procedural Terminology [CPT] 27130) performed from 2015 to 2018 was conducted. Patient demographics, American Society of Anesthesiologists (ASA) classification, functional status, NSQIP morbidity probability, operative time, length of stay (LOS), 30-day reoperation rate, readmission rate, and associated complications were collected. Results: A total of 2,896 patients underwent outpatient classified THA. The mean age of patients was 61.2 years. The mean body mass index (BMI) was 29.6 kg/m 2 with median ASA 2. The results of univariate comparison of SNF/rehab versus home discharge showed that a significantly higher percentage of females (58.7% vs. 46.8%), age >70 years (49.3% vs. 20.9%), ASA ≥3 (58.0% vs. 25.8%), BMI >35 kg/m 2 (23.3% vs. 16.2%), and hypoalbuminemia (8.0% vs. 1.5%) (P<0.0001) were discharged to SNF/rehab. The results of multivariable logistic regression showed that female sex (odds ratio [OR] 1.47; P=0.03), age >70 years (OR 3.08; P=0.001), ASA≥3 (OR 2.56; P=0.001), and preoperative hypoalbuminemia (<3.5 g/dL) (OR 3.76; P=0.001) were independent risk factors for SNF/rehab discharge. Conclusion Risk factors associated with discharge to a SNF/rehab after outpatient classified THA were identified. Surgeons will be able to perform better risk stratification for patients who may require additional postoperative intervention.

OBJECTIVE: To preliminarily explore the potential effect of β-glucan on Chinese medicine (CM) concept protective qi deficiency (PQD), and the methodology for future definitive studies. METHODS: To have a standardized assessment of PQD, a list of 13 potentially PQD-relevant parameters were firstly created, each with defined quantitative or categorial scales. Using the data from 37 participants with (21 cases) or without (16 cases) PQD, multivariate logistic modeling was conducted to create a preliminary diagnostic PQD risk score. Subsequently, 21 participants diagnosed with PQD were treated with β-glucan in a dose of 200 mg/day for 8 weeks. Data were collected for trial acceptability measures (rate of recruitment, withdrawal, and compliance), and the participants were assessed for PQD status at baseline and every 2 weeks thereafter. RESULTS: The preliminary logistic model consisted of 3 parameters (low voice and apathy, aversion to wind and cold, and Cun pulse). The resulting risk score demonstrated a degree of PQD-predicting accuracy that, as evaluated by statistical (discrimination and classification) methods, was higher than those obtained from any of the individual candidate parameters. The 21 PQD participants treated with β-glucan demonstrated good receptibility and a time-dependent improvement in PQD status as evidenced by the decrease of PQD participant to 9.5% at the end of study. CONCLUSIONS This study demonstrated the effect of proof-of-concept of β-glucan on improving PQD and the proof-of-concept of a multivariate-model-derived diagnostic PQD risk score. It also indicated feasibility for future definitive studies. Studies like this embody an innovative approach that uses therapies derived from the mainstream biomedicine to enrich therapeutics guided by CM principle. (Trial registration No. NCT03829228).

In the original publication the bands in Fig. 1J and Fig. 2B were not visible. The correct versions of Fig. 1J and Fig. 2B are provided in this correction.

BACKGROUND/AIMS: Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) remains the most common EUS-guided tissue acquisition technique. This study aimed to evaluate the performance of a new Franseen tip fine needle biopsy (FNB) device for EUSguided sampling of solid lesions and compare it with the historical FNA technique. METHODS: Acquire® 22 G FNB needle (Boston Scientific Co., Natick, MA, USA) was used for solid tumor sampling (Study group). Tissue was collected for rapid on-site evaluation, and touch and crush preparations were made. Historical EUS-FNA samples obtained using Expect® 22 G FNA needle (Boston Scientific Co.) were used as controls (Control group). All specimens were independently evaluated by two cytopathologists blinded to the formal cytopathological diagnosis. RESULTS: Mean cell block histology scores were significantly higher (p=0.046) in the FNB group (51 samples) despite a significantly lower (p < 0.001) mean number of passes compared to the FNA group (50 specimens). The overall diagnostic yields for the FNB vs. FNA groups were 96% vs. 88%. The degree of tumor differentiation was adequately assessed in all cell block qualifying lesions in the FNB group. Two patients developed post-FNB abdominal pain. CONCLUSIONS: The new Franseen tip FNB device provides histologically superior and cytologically comparable specimens to those obtained by FNA, but with fewer passes.
Abdominal Pain ; Biopsy, Fine-Needle* ; Diagnosis ; Endoscopic Ultrasound-Guided Fine Needle Aspiration ; Humans ; Needles ; Prospective Studies*

Asthma ; complications ; therapy ; Humans ; Invasive Pulmonary Aspergillosis ; complications ; drug therapy ; Male ; Middle Aged ; Pulmonary Disease, Chronic Obstructive ; complications ; therapy

Catalytic Domain ; Enzyme Inhibitors ; metabolism ; pharmacology ; Influenza A Virus, H1N1 Subtype ; enzymology ; Models, Molecular ; Mutation ; Neuraminidase ; antagonists & inhibitors ; chemistry ; genetics ; metabolism ; Protein Binding

We report a significantly-enhanced bioinformatics suite and database for proteomics research called Yale Protein Expression Database (YPED) that is used by investigators at more than 300 institutions worldwide. YPED meets the data management, archival, and analysis needs of a high-throughput mass spectrometry-based proteomics research ranging from a single laboratory, group of laboratories within and beyond an institution, to the entire proteomics com-munity. The current version is a significant improvement over the first version in that it contains new modules for liquid chromatography–tandem mass spectrometry (LC–MS/MS) database search results, label and label-free quantitative proteomic analysis, and several scoring outputs for phosphopeptide site localization. In addition, we have added both peptide and protein comparative analysis tools to enable pairwise analysis of distinct peptides/proteins in each sample and of overlapping peptides/proteins between all samples in multiple datasets. We have also implemented a targeted proteomics module for automated multiple reaction monitoring (MRM)/selective reaction monitoring (SRM) assay development. We have linked YPED’s database search results and both label-based and label-free fold-change analysis to the Skyline Panorama repository for online spectra visualization. In addition, we have built enhanced functionality to curate peptide identifications into an MS/MS peptide spectral library for all of our protein database search identification results.